Previous 10 | Next 10 |
AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, provided an update on ongoing OT-101/IL-2 combination trial (the “Trial”...
AGOURA HILLS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology today announced an update on the Phase 2 C001 Covid Study and the O...
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , executed an exclusive licensing agreement on September 30, 2021, wit...
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to...
AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19, reported today that PulmoHeal TM / ArtiVeda TM has...
AGOURA HILLS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19 and Golden Mountain Partners, ( “ GMP ”...
Oncotelic Therapeutics ([[OTLC]]) announces that, as of June 11, it has discontinued enrollment in its OT-101 clinical trial in patients with COVID-19.The trial completed randomization of 32 out of 36 patients planned, on an intent to treat basis. “Due to the continuing rise of more se...
AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology, infectious diseases and respiratory health announced that, as of June 11, 20...
AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundatio...
Oncotelic Therapeutics ([[OTLC]] -4.6%) posts positive topline data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal against COVID-19 in India.PulmoHeal, which is being developed by Oncotelic in partnership with Windlas Biotech Private, when added to the sta...
News, Short Squeeze, Breakout and More Instantly...
Oncotelic Therapeutics Inc Company Name:
OTLC Stock Symbol:
OTCMKTS Market:
Oncotelic Therapeutics Inc Website:
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. ...
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event ...
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, ov...